Following the path of most resistance: Dhps K540E dispersal in African Plasmodium falciparum

Trends in Parasitology

Volumn 26, Issue 9, 2010, Pages 447-456

  Naidoo, Inbarani ^a,b   Roper, Cally ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLOROQUINE; PYRIMETHAMINE; SULFADOXINE;

AFRICA; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; IMMUNOSURVEILLANCE; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; PLASMODIUM FALCIPARUM; POINT MUTATION; PREVALENCE; REVIEW; SEQUENCE ANALYSIS; TREATMENT FAILURE;

AFRICA; ANIMALS; ANTIMALARIALS; CHLOROQUINE; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POINT MUTATION; POPULATION SURVEILLANCE; PREVALENCE; PYRIMETHAMINE; SULFADOXINE;

PLASMODIUM FALCIPARUM;

EID: 77955924411     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.05.001     Document Type: Review

References (64)

1. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
2. Enserink, M. (2008) Malaria. Signs of drug resistance rattle experts, trigger bold plan. Science DOI: 10.1126/science.322.5909.1776 (). http://www.sciencemag.org/.
3. Fidock D.A., et al. Mutations in the P. falciparum digestive vacuole transmembrane protein pfcrt and evidence for their role in chloroquine resistance. Mol. Cell 2000, 6:861-871.
4. Cowman A.F., et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9109-9113.
5. Peterson D.S., et al. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9114-9118.
6. Brooks D.R., et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 1994, 224:397-405.
7. Triglia T., Cowman A.F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:7149-7153.
8. World Health Organisation The epidemiology of drug resistance of malaria parasites: memorandum from a WHO meeting. Bull. World Health Organ. 1987, 65:797-816.
9. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol. Today 1987, 3:241-246.
10. Charmot G., et al. [Geographic approach to the epidemiology of chloroquine-resistance of Plasmodium falciparum in tropical Africa]. Ann. Soc. Belg. Med. Trop. 1991, 71:187-197.
11. Wootton J.C., et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418:320-323.
12. Ariey, F. et al. (2006) Invasion of Africa by a single pfcrt allele of South East Asian type. Malar. J. DOI: 10.1186/1475-2875-5-34 (). http://www.malariajournal.com/.
13. Adubofour K.O. Drug resistance in malaria: a review of the west African situation. J. Natl. Med. Assoc. 1992, 84:1025-1029.
14. Peters W. Chemotherapy and Drug Resistance in Malaria 1987, Academic Press Limited.
15. Clyde D.F. Malaria in Tanzania 1967, Oxford University Press.
16. Newton P.N., et al. Murder by fake drugs. BMJ 2002, 324:800-801.
17. World Health Organisation (2005) Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring: 1996-2004.WHO/HTM/MAL/2005.1103 (). http://malaria.who.int/.
18. Roper C., et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174-1181.
19. Certain L.K., et al. Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987-2006. J. Infect. Dis. 2008, 197:1743-1751.
20. Mita T., et al. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol. Int. 2009, 58:201-209.
21. Menegon M., et al. Monitoring for multidrug-resistant Plasmodium falciparum isolates and analysis of pyrimethamine resistance evolution in Uige province, Angola. Trop. Med. Int. Health 2009, 14:1251-1257.
22. Roper C., et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004, 305:1124.
23. Ndiaye D., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop. Med. Int. Health 2005, 10:1176-1179.
24. McCollum A.M., et al. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J. Infect. Dis. 2006, 194:189-197.
25. Maiga O., et al. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J. Infect. Dis. 2007, 196:165-172.
26. Lynch C., et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J. Infect. Dis. 2008, 197:1598-1604.
27. Ronn A.M., et al. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans. R. Soc. Trop. Med. Hyg. 1996, 90:179-181.
28. Trigg J.K., et al. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Trop. 1997, 63:185-189.
29. White N.J. Antimalarial drug resistance: the pace quickens. J. Antimicrob. Chemother. 1992, 30:571-585.
30. Pearce, R.J. et al. (2009) Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. DOI: 10.1371/journal.pmed.1000055 (). http://www.plosmedicine.org/.
31. Omar S.A., et al. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:315-319.
32. Staedke S.G., et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 2004, 9:624-629.
33. Kublin J.G., et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
34. Hastings, I.M. and Smith, T.A. (2008) MalHaploFreq: a computer programme for estimating malaria haplotype frequencies from blood samples. Malar. J. DOI: 10.1186/1475-2875-7-130 (). http://www.malariajournal.com/.
35. Nzila A.M., et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 2000, 44:991-996.
36. Curtis J., et al. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J. Infect. Dis. 1998, 177:1429-1433.
37. Plowe C.V., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis. 1997, 176:1590-1596.
38. Barnes K.I., et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J. Infect. Dis. 2008, 197:1605-1613.
39. Alifrangis M., et al. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. Am. J. Trop. Med. Hyg. 2003, 69:601-606.
40. Mkulama, M.A. et al. (2008) Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia. Malar. J. DOI: 10.1186/1475-2875-7-87 (). http://www.malariajournal.com/.
41. Alker A.P., et al. dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health 2008, 13:1384-1391.
42. Cohuet S., et al. Short report: molecular markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo. Am. J. Trop. Med. Hyg. 2006, 75:152-154.
43. Happi C.T., et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005, 95:183-193.
44. Bonnet, M. et al. (2007) Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zerekore. Malar. J. DOI: 10.1186/1475-2875-6-54 (). http://www.malariajournal.com/.
45. Dicko, A. et al. (2010) Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar. J. DOI: 10.1186/1475-2875-9-9 (). http://www.malariajournal.com/.
46. Dokomajilar C., et al. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am. J. Trop. Med. Hyg. 2006, 75:162-165.
47. Tinto H., et al. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am. J. Trop. Med. Hyg. 2007, 76:608-613.
48. Dunyo, S. et al. (2006) Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin. Trials DOI: 10.1371/journal.pctr.0010014 (). http://clinicaltrials.ploshubs.org/.
49. Kofoed P.E., et al. Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau. Trop. Med. Int. Health 2004, 9:171-177.
50. Djaman J.A., et al. Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Cote d'Ivoire. Ann. Trop. Med. Parasitol. 2007, 101:103-112.
51. Checchi F., et al. High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations. Trans. R. Soc. Trop. Med. Hyg. 2002, 96:664-669.
52. Andriantsoanirina V., et al. Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob. Agents Chemother. 2009, 53:4588-4597.
53. Eberl K.J., et al. Prevalence of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from southern Mauritania. Trop. Med. Int. Health 2001, 6:756-760.
54. Ibrahim, M.L. et al. (2009) Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. Malar. J. DOI: 10.1186/1475-2875-8-32 (). http://www.malariajournal.com/.
55. Ndiaye D., et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Senegal. Trop. Med. Int. Health 2005, 10:1176-1179.
56. Cisse, B. et al. (2009) Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE DOI: 10.1371/journal.pone.0007164 (). http://www.plosone.org/.
57. Berzosa P.J., et al. Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes. Parasitol. Res. 2005, 97:287-289.
58. Abdel-Muhsin A.M., et al. Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan. J. Infect. Dis. 2004, 189:1239-1244.
59. Rogier C., et al. Malaria epidemic and drug resistance, Djibouti. Emerg. Infect. Dis. 2005, 11:317-321.
60. Tatem A.J. The worldwide airline network and the dispersal of exotic species: 2007-2010. Ecography 2009, 32:94-102.
61. White N.J., et al. Averting a malaria disaster. Lancet 1999, 353:1965-1967.
62. Barnes K.I., et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 2006, 80:582-596.
63. Nair S., et al. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol. Biol. Evol. 2007, 24:562-573.
64. Omumbo J.A., Snow R.W. Plasmodium falciparum parasite prevalence in East Africa: a review. East Afr. Med. J. 2004, 81:649-656.